SCHEMBL4899048

SCHEMBL4899048

O=C(CCl)c1ccc(Cl)nc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NAPRT Q6XQN6 1/20 0.62
GSK3B P49841 2/20 0.55
GRM4 Q14833 4/20 0.53
RAB9A P51151 4/20 0.50
NPC1 O15118 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.49
MAPT P10636 2/20 0.49
DGAT1 O75907 2/20 0.47
POLB P06746 2/20 0.47
TRPA1 O75762 1/20 0.47
ALDH1A1 P00352 1/20 0.47
MAPK1 P28482 1/20 0.47
HIF1A Q16665 1/20 0.47
PKM P14618 1/20 0.45
KCNQ3 O43525 1/20 0.45
KCNQ2 O43526 1/20 0.45
KCNE1 P15382 1/20 0.45
KCNQ1 P51787 1/20 0.45
MEN1 O00255 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4894083 0.98 NAPRT (0.60) NAPRTGSK3BGRM4RAB9ANPC1
SCHEMBL1985578 0.86 NAPRT (0.64) NAPRTGRM4RAB9ANPC1SMN1; SMN2
SCHEMBL6439911 0.84 NAPRT (0.62) NAPRTGRM4RAB9ANPC1SMN1; SMN2
SCHEMBL6389786 0.82 NAPRT (0.60) NAPRTGRM4RAB9ANPC1SMN1; SMN2
SCHEMBL30093343 0.82 NAPRT (0.60) NAPRTGSK3BGRM4RAB9ANPC1
SCHEMBL30175321 0.82 NAPRT (0.60) NAPRTGRM4RAB9ANPC1SMN1; SMN2
SCHEMBL196686 0.82 NAPRT (0.60) NAPRTGSK3BGRM4RAB9ANPC1
SCHEMBL1877325 0.82 NAPRT (0.60) NAPRTGRM4RAB9ANPC1SMN1; SMN2
SCHEMBL3299695 0.82 NAPRT (0.55) NAPRTGRM4RAB9ANPC1SMN1; SMN2
Hydrochloric Acid SCHEMBL12098974 0.81 NAPRT (0.58) NAPRTGRM4RAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080255364-A1 Method For The Production A-Chloroalkylpyridyl Ketones And/Or The Hydrochlorides Thereof BASF AKTIENGESELLSCHAFT (DE) 2008-10-16 US claimed
EP-1751110-A1 METHOD FOR THE PRODUCTION OF A-CHLOROALKYLPYRIDYL KETONES AND/OR THE HYDROCHLORIDES THEREOF BASF AKTIENGESELLSCHAFT (DE) 2007-02-14 EP claimed
WO-2005113505-A1 METHOD FOR THE PRODUCTION OF A-CHLOROALKYLPYRIDYL KETONES AND/OR THE HYDROCHLORIDES THEREOF BASF AKTIENGESELLSCHAFT (DE) 2005-12-01 WO claimed
US-20250051316-A1 2-(ARYL-2-YL) MORPHOLINE AND DEUTERATED DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2025-02-13 US disclosed
EP-4428128-A1 2-(ARYL-2-YL) MORPHOLINE AND DEUTERATED DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2024-09-11 EP disclosed
WO-2023078392-A1 2-(ARYL-2-YL) MORPHOLINE AND DEUTERATED DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 上海翰森生物医药科技有限公司 2023-05-11 WO disclosed
WO-2023078392-A1 2-(ARYL-2-YL) MORPHOLINE AND DEUTERATED DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF 上海翰森生物医药科技有限公司 2023-05-11 WO disclosed
EP-3116858-B1 AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC (JP) 2020-11-11 EP disclosed
US-20180339993-A1 AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS RAQUALIA PHARMA INC. (JP) 2018-11-29 US disclosed
US-10093678-B2 Azaspiro derivatives as TRPM8 antagonists RAQUALIA PHARMA INC. (JP) 2018-10-09 US disclosed
EP-2688870-B1 HETEROCYCLIC AMINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2017-02-01 EP disclosed
WO-2012123298-A1 ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2012-09-20 WO disclosed
US-20120230951-A1 ANTIVIRAL COMPOUNDS ALAM MUZAFFAR (US) 2012-09-13 US disclosed
US-20080255364-A1 Method For The Production A-Chloroalkylpyridyl Ketones And/Or The Hydrochlorides Thereof BASF AKTIENGESELLSCHAFT (DE) 2008-10-16 US disclosed
US-20080255364-A1 Method For The Production A-Chloroalkylpyridyl Ketones And/Or The Hydrochlorides Thereof BASF AKTIENGESELLSCHAFT (DE) 2008-10-16 US disclosed
US-20080255364-A1 Method For The Production A-Chloroalkylpyridyl Ketones And/Or The Hydrochlorides Thereof BASF AKTIENGESELLSCHAFT (DE) 2008-10-16 US disclosed
EP-1751110-A1 METHOD FOR THE PRODUCTION OF A-CHLOROALKYLPYRIDYL KETONES AND/OR THE HYDROCHLORIDES THEREOF BASF AKTIENGESELLSCHAFT (DE) 2007-02-14 EP disclosed
WO-2005113505-A1 METHOD FOR THE PRODUCTION OF A-CHLOROALKYLPYRIDYL KETONES AND/OR THE HYDROCHLORIDES THEREOF BASF AKTIENGESELLSCHAFT (DE) 2005-12-01 WO disclosed
EP-0506729-A1 PHARMACEUTICALLY ACTIVE OXAZOLE COMPOUNDS Beecham Group p.l.c. (GB) 1992-10-07 EP disclosed
WO-1991009856-A1 PHARMACEUTICALLY ACTIVE OXAZOLE COMPOUNDS BEECHAM GROUP PLC (GB) 1991-07-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250051316-A1 2-(ARYL-2-YL) MORPHOLINE AND DEUTERATED DERIVATIVE THEREOF, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF TAAR1, TAAR5, AVPR2 NAPRT 1520/4885GSK3B 1561/4885GRM4 752/4885
US-10093678-B2 Azaspiro derivatives as TRPM8 antagonists TRPM8, TRPM7, TRPM5 NAPRT 271/4885GSK3B 2725/4885GRM4 889/4885
US-20180339993-A1 AZASPIRO DERIVATIVES AS TRPM8 ANTAGONISTS TRPM8, TRPM7, TRPM6 NAPRT 285/4885GSK3B 2584/4885GRM4 870/4885
US-20120230951-A1 ANTIVIRAL COMPOUNDS HAVCR2, EIF2AK2, MAVS NAPRT 2242/4885GSK3B 575/4885GRM4 3914/4885
US-20080255364-A1 Method For The Production A-Chloroalkylpyridyl Ketones And/Or The Hydrochlorides Thereof CBS, PCCA, ALK NAPRT 3586/4885GSK3B 3329/4885GRM4 4562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.